Agile Therapeutics (AGRX) has released an update.
Agile Therapeutics has amended its credit agreement with Perceptive, extending the loan maturity date to March 11, 2024, and will continue monthly payments of $150,000 until then. The company also received a Nasdaq notice granting an extension until March 25, 2024, to meet stockholders’ equity requirements or face delisting, which could negatively impact stock liquidity and capital raising. Despite forward-looking statements, there’s no certainty in regaining compliance or avoiding delisting, which carries risks for the company’s financial future and stock performance.
For further insights into AGRX stock, check out TipRanks’ Stock Analysis page.
